CD
Carl Dambkowski (Director) filed 12 Form 4 reports in the trailing twelve months (0 purchases, 12 sales), most often in Apogee Therapeutics, Inc. (APGE). The largest single filing was $6.2M of ORKA (105,000 sh across 3 lots, as filed), executed May 21. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
12
0 buys · 12 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$17.7M
shares × price, as filed
Last traded
Aug 5
Filed Aug 7
Median ADV $371.2M across their filed names
Open performance→Volume by month
Buys $0
Sells $19.9M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
12 filings
Sector per market data · by filing · past 12 months
Most traded names
APGERecent filings
APGESALE
Apogee Therapeutics, Inc.
View filing →
$101K2,725 sh × $36.96
Exec Jun 4 2025
Filed Jun 6 2025 · 5:30 PM ET APGESALE Apogee Therapeutics, Inc. View filing → $143K
3,520 sh × $40.69
Exec Feb 5 2025
Filed Feb 7 2025 · 5:30 PM ET APGESALE Apogee Therapeutics, Inc. View filing → $117K
2,486 sh × $47.21
Exec Jan 2 2025
Filed Jan 3 2025 · 5:30 PM ET APGESALE Apogee Therapeutics, Inc. View filing → $199K
4,085 sh × $48.62
Exec Dec 11 2024
Filed Dec 13 2024 · 5:30 PM ET APGESALE Apogee Therapeutics, Inc. View filing → $307K
6,665 sh × $46.07
Exec Dec 4 2024
Filed Dec 6 2024 · 5:30 PM ET APGESALE Apogee Therapeutics, Inc. View filing → $314K
5,326 sh × $58.91
Exec Nov 6 2024
Filed Nov 8 2024 · 5:30 PM ET